WO2005055927A2 - Compositions and methods for topical treatment of skin infection - Google Patents
Compositions and methods for topical treatment of skin infection Download PDFInfo
- Publication number
- WO2005055927A2 WO2005055927A2 PCT/US2004/040038 US2004040038W WO2005055927A2 WO 2005055927 A2 WO2005055927 A2 WO 2005055927A2 US 2004040038 W US2004040038 W US 2004040038W WO 2005055927 A2 WO2005055927 A2 WO 2005055927A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- magnesium
- aluminum
- bismuth
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- Topical acne treatment commonly includes prescription-required antibiotics (such as erythromycin and clindamycin) and potent retinoids.
- antibiotics such as erythromycin and clindamycin
- potent retinoids potent retinoids
- the present invention relates to the surprising discovery that topical application of mixtures containing one or more polyvalent metal compounds can effectively heal the acne and warts in humans when applied from an appropriate dosage form.
- complete healing without any scars left behind (Examples I and II) was found in several subjects within one day after only one single application.
- pustular inflammatory acne virtually complete healing was found in just about one to two days of treatment (Examples I to III).
- example IN For very severe chronic, multiple-lesion acne, a dramatic effect was observed in 6 days (Example IN).
- warts a crust was formed and healing was found to begin shortly after one application. Near healing was found in about one week.
- the present method can also be used for promoting health of oral mucous membranes and tissues by regular use of tooth paste, mouth wash, gel or paste that contains an effective and safe amount of a magnesium compound.
- the word “treatment” or “treating” includes ameliorating the symptoms of, curing or healing, and preventing the development of a given disease such as acne and warts.
- the phrase “effective amount” refers to that amount of a compound which is sufficient to effect safe treatment when administered to a mammal in need of such treatment or prevention.
- prevention refers to prophylaxis.
- scar refers to a mark left on the skin after a wound, burn, ulcer, pustule, lesion, etc. has healed.
- the words “healing or sloughing” as they relate to scar provide regenerating a new skin tissue to replace the scarred tissue.
- polyvalent metal compound refers to any organic or inorganic polyvalent compound that has the beneficial therapeutic properties described herein.
- Polyvalent metal compounds include, but are not limited to, aluminum compounds, magnesium compounds, zinc compounds, calcium compounds, bismuth compounds, titanium compounds, copper compounds, manganese compounds, iron compounds, chromium compounds, selenium compound, and barium compounds.
- a polyvalent compound can be an inorganic or organic salt, an oxide or a complex.
- the counter ion to a metal or the ligand moiety to a metal is also therapeutically active or can enhance the therapeutic activity of the metal moiety.
- One such example may be magnesium salicylate since salicylate is known to have an anti-inflammatory property.
- Suitable dosage forms of one or more polyvalent metal compounds include, but are not limited to, a liquid solution or mixture with various viscosity, a suspension, a gel, a cream, a lotion, an emulsion, a paste, a spray, and a medicated bandage or patch. Pure fine powders or diluted fine powders can also be applied to the open lesion area.
- the method to prepare a dosage form is based on the standard principles and methods described in various pharmaceutical literature. It is impossible to list all of the potential polyvalent metal compounds that may be useful in the present invention.
- the therapeutically effective compound is selected from the group consisting of calcium acetate, calcium alginate, calcium benzoate, calcium carbonate, calcium chloride, calcium citrate, calcium gluconate, calcium hydroxide, calcium lactate, calcium phosphate, calcium stearate, calcium sulfate, calcium salicylate calcium oxide, and other calcium-containing compounds.
- the therapeutically effective compound is selected from the group consisting of copper gluconate, copper salicylate, copper sulfate, and other copper-containing compounds.
- the therapeutically effective compound is selected from the group consisting of titanium dioxide, titanium peroxide, titanium salicylate, titanium tannate, and other titanium-containing compounds.
- the concentration of a polyvalent metal compound for the treatment of acne, warts and rosacea and for the prevention of scar formation, for depigmentation (Example I) or for the healing or elimination of the scar formed or for the prophylaxis and treatment of periodontitic and tooth mobility in a dosage form will be about 0.001% to about 50% by weight.
- Other embodiments contain about 0.1% to about 40%, about 0.5% to about 30%, or about 1.0% to about 10% by weight of polyvalent metal compounds.
- An effective amount of one or more polyvalent metal compounds may also be applied daily to vulnerable skin areas for prophylactic purpose in acne management or to the gum and teeth for prevention of periodontitis and tooth mobility, as well as for promoting healthy growth of oral tissue.
- any compound or compounds that may further enhance the efficacy of the polyvalent compounds in the treatment of acne, warts, periodontitis or tooth mobility as well as in the promotion of health of oral mucous membranes and tissues can also be incorporated into the dosage form; this may include an anti- inflammatory compound.
- Skin-peeling compounds such as lactic acid, citric acid and salicylic acid as well as other absorption enhancers such as glycyrrhizin may also be added to increase the absorption through the skin.
- the present invention is also useful for prevention and treatment of scar and for depigmentation.
- the present invention is illustrated by the following non-limiting examples. The percentages of ingredients are by weight.
- Example I An Aqueous Glycerin Solution Containing 10%) Aluminum Potassium Sulfate, 8% Magnesium Sulfate and 1% Zinc Gluconate for Acne Treatment and for Depigmentation
- the above solution containing about 70% of glycerin was topically applied once to three adults with an inflammatory papular acne on the face.
- the papule in two adults was found to disappear the following day with no flare-ups in the following weeks.
- the third adult had the redness and bump of a papule markedly reduced the following day. Without any additional treatment the redness and bump were completely gone after about ten days.
- the fourth adult applied the solution to the area of lesion with an inflammatory papule three times a day.
- Example N A Polyvalent Metal Suspension for Treatment of Warts
- a male adult developed a typical wart with bleeding on his right side of the face for a few weeks.
- a small amount of a suspension containing about 10% aluminum potassium sulfate, 10% magnesium sulfate and 2% zinc acetate in glycerin was applied to the area of lesion and covered with a bandage. The following day a hanging dark brown tissue was removed. The metal suspension was applied three times on that day and the lesion was found to begin to dry and to heal. The suspension was applied two times the following day without a bandage. The area of the lesion got smaller every day and in about one week only a small needle- size bump was present.
- a 10% aluminum potassium sulfate in glycerin- water mixture was later tried for three days and the lesion was completely healed without any scar left in a few days.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002539003A CA2539003A1 (en) | 2003-12-04 | 2004-11-30 | Compositions and methods for topical treatment of skin infection |
JP2006542673A JP2007513162A (en) | 2003-12-04 | 2004-11-30 | Compositions and methods for topical treatment of skin infections |
GB0612417A GB2426454A (en) | 2003-12-04 | 2004-11-30 | Compositions and methods for topical treatment of skin infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/727,376 | 2003-12-04 | ||
US10/727,376 US7258875B2 (en) | 2003-12-04 | 2003-12-04 | Compositions and methods for topical treatment of skin infection |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005055927A2 true WO2005055927A2 (en) | 2005-06-23 |
WO2005055927A3 WO2005055927A3 (en) | 2006-11-09 |
Family
ID=34633471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/040038 WO2005055927A2 (en) | 2003-12-04 | 2004-11-30 | Compositions and methods for topical treatment of skin infection |
Country Status (7)
Country | Link |
---|---|
US (2) | US7258875B2 (en) |
JP (1) | JP2007513162A (en) |
CN (1) | CN101262871A (en) |
CA (1) | CA2539003A1 (en) |
GB (1) | GB2426454A (en) |
TW (1) | TW200520762A (en) |
WO (1) | WO2005055927A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2940121A1 (en) * | 2008-12-23 | 2010-06-25 | Oreal | Composition for the care of greasy skin, especially for eliminating bacteria responsible for acne, contains a combination of phthalamidoperhexanoic acid and zinc salicylate |
EP2233128A1 (en) | 2009-03-25 | 2010-09-29 | Cognis IP Management GmbH | Cosmetic composition |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8734421B2 (en) | 2003-06-30 | 2014-05-27 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating pores on the skin with electricity |
WO2006117885A1 (en) * | 2005-04-28 | 2006-11-09 | Cosmo Oil Co., Ltd. | External preparation for skin |
US7687650B2 (en) | 2006-02-03 | 2010-03-30 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7897800B2 (en) | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
WO2007089267A1 (en) | 2006-02-03 | 2007-08-09 | Jr Chem, Llc | Anti-aging treatment using copper and zinc compositions |
US20090246292A1 (en) * | 2006-02-21 | 2009-10-01 | Syntopix Limited | Antimicrobial formulations comprising a quinone and a copper salt |
GB0618697D0 (en) * | 2006-09-22 | 2006-11-01 | Syntopix Ltd | Formulations |
US7867522B2 (en) | 2006-09-28 | 2011-01-11 | Jr Chem, Llc | Method of wound/burn healing using copper-zinc compositions |
US8703104B2 (en) * | 2007-10-25 | 2014-04-22 | Ecolab Usa Inc | Use of metal astringents for the treatment of hairy heel warts |
US8273791B2 (en) | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
US9642877B1 (en) * | 2016-01-06 | 2017-05-09 | Kenneth O. Russell | Method of administration of chromium and magnesium sulfate for treatment of acne |
US20090297610A1 (en) * | 2008-06-03 | 2009-12-03 | Colorescience, Inc. | Composition and system to promote wound healing |
US20100003315A1 (en) * | 2008-07-02 | 2010-01-07 | Willeford Kenneth L | Method and Composition for the Treatment of Skin Conditions |
US20100003314A1 (en) * | 2008-07-02 | 2010-01-07 | Willeford Kenneth L | Method and composition for the treatment of skin conditions |
US8846646B2 (en) * | 2008-10-03 | 2014-09-30 | Winlind Skincare, Llc | Topical treatment of skin infection |
US8513225B2 (en) * | 2008-10-03 | 2013-08-20 | Winlind Skincare, Llc | Composition and method for topical treatment of skin lesions |
FR2940122B1 (en) * | 2008-12-23 | 2012-04-27 | Oreal | COMPOSITION FOR SKIN CARE |
WO2010085753A1 (en) | 2009-01-23 | 2010-07-29 | Jr Chem, Llc | Rosacea treatments and kits for performing them |
US20120089232A1 (en) | 2009-03-27 | 2012-04-12 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
US20110008271A1 (en) | 2009-07-13 | 2011-01-13 | Jr Chem, Llc | Rosacea treatments using polymetal complexes |
GB2482400A (en) | 2010-07-28 | 2012-02-01 | Syntopix Group Plc | Antibacterial formulation containing a tropone and a metal or metal salt |
GB201021745D0 (en) * | 2010-12-22 | 2011-02-02 | Syntopix Group Plc | Formulations |
US8952057B2 (en) | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
GB201110278D0 (en) | 2011-06-17 | 2011-08-03 | Syntopix Group Plc | Formulations |
RU2482856C2 (en) | 2011-08-05 | 2013-05-27 | Общество С Ограниченной Ответственностью "Оксигон" | Complex compound of zinc 2-chloropropionate and 2-chloropropionic acid, pharmaceutical composition for treating skin diseases, method for preparing it and method for treating skin, nail and visible mucosal disorders |
CN105307664A (en) * | 2013-03-07 | 2016-02-03 | 凯恩生物科技有限公司 | Antimicrobial-antibiofilm compositions and methods of use thereof |
US10357470B2 (en) | 2013-03-07 | 2019-07-23 | Kane Biotech Inc. | Antimicrobial-antibiofilm compositions and methods of use thereof |
US11083750B2 (en) | 2013-03-15 | 2021-08-10 | Cda Research Group, Inc. | Methods of treatment using topical copper ion formulations |
US11318089B2 (en) | 2013-03-15 | 2022-05-03 | Cda Research Group, Inc. | Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body |
US11007143B2 (en) | 2013-03-15 | 2021-05-18 | Cda Research Group, Inc. | Topical copper ion treatments and methods of treatment using topical copper ion treatments in the oral-respiratory-otic areas of the body |
US11000545B2 (en) | 2013-03-15 | 2021-05-11 | Cda Research Group, Inc. | Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza |
US10398733B2 (en) | 2013-03-15 | 2019-09-03 | Cda Research Group, Inc. | Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body |
DE202014010979U1 (en) * | 2013-12-17 | 2017-02-23 | Mary Kay Inc . | Applicator devices for skincare products |
CN107105749A (en) * | 2014-08-13 | 2017-08-29 | 阿克索生物医药公司 | Antimicrobe compound and composition and application thereof |
WO2016205089A1 (en) | 2015-06-17 | 2016-12-22 | Profet Margaret Jean | Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne |
US10653658B2 (en) | 2015-08-11 | 2020-05-19 | Akeso Biomedical, Inc. | Biofilm inhibiting compositions enhancing weight gain in livestock |
CN108024563A (en) | 2015-08-11 | 2018-05-11 | 艾索生物医药公司 | Improve the increased biomembrane composite inhibiting of weight in domestic animal |
CN105169375A (en) * | 2015-08-21 | 2015-12-23 | 吕欢 | Compound lozenge controlling childe tooth decay |
JP6840324B2 (en) * | 2017-03-13 | 2021-03-10 | 日本メナード化粧品株式会社 | Topical skin for acne prevention and / or improvement |
WO2018204711A1 (en) * | 2017-05-03 | 2018-11-08 | BioPharmX, Inc. | Magnesium chloride composition for dermatological use |
US10456366B2 (en) | 2017-11-29 | 2019-10-29 | Chiou Consulting, Inc. | Composition and methods for tissue regeneration |
US11193184B2 (en) | 2019-02-22 | 2021-12-07 | Cda Research Group, Inc. | System for use in producing a metal ion suspension and process of using same |
CN110698883B (en) * | 2019-09-17 | 2021-09-24 | 河南佰利联新材料有限公司 | Titanium dioxide pigment and preparation method thereof |
JP2021020891A (en) * | 2020-07-04 | 2021-02-18 | 朋美 鳥山 | Magnesium salt composition and production method thereof |
JP2021176834A (en) * | 2021-01-29 | 2021-11-11 | 朋美 鳥山 | Magnesium salt composition obtained by mixing magnesium chloride and magnesium sulfate in fixed ratio range, and production method thereof |
CN113768810A (en) * | 2021-10-13 | 2021-12-10 | 陕西恒远生物科技有限公司 | Whitening cream with self-protection function and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4595591A (en) * | 1979-09-27 | 1986-06-17 | Solco Basel Ag | Use of dilute nitric acid solutions for treating certain skin lesions |
US5866168A (en) * | 1995-10-26 | 1999-02-02 | Societe L'oreal S.A. | Dermatological/pharmaceutical compositions comprising lanthanide, manganese, tin, zinc, yttrium, cobalt, barium and/or strontium salts as substance P antagonists |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053630A (en) * | 1976-07-07 | 1977-10-11 | Yu Ruey J | Treatment of body odor and disturbed keratinization |
US4224339A (en) * | 1978-10-10 | 1980-09-23 | Scott Eugene J Van | Treatment of disturbed keratinization |
US5514667A (en) * | 1990-11-05 | 1996-05-07 | Arthropharm Pty. Limited | Method for topical treatment of herpes infections |
US5149691A (en) * | 1991-03-12 | 1992-09-22 | Creative Biomolecules, Inc. | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
DE59101214D1 (en) * | 1991-07-15 | 1994-04-21 | Artesan Pharma Gmbh | Use of ascorbic acid in the preparation of medicinal products for use in the genital area. |
US5898037A (en) * | 1992-11-13 | 1999-04-27 | Marx; Alvin J. | Formulations of magnesium compounds for local application and methods of treatment using the same |
IT1256111B (en) * | 1992-11-23 | 1995-11-28 | Lifegroup Spa | SALTS OF TRAUMATIC ACID WITH CICATRIZING AND ANTIBACTERIAL ACTIVITY |
US6372784B1 (en) * | 1995-02-07 | 2002-04-16 | Josman Laboratories, Inc. | Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds |
EP0737471A3 (en) * | 1995-04-10 | 2000-12-06 | L'oreal | Use of alkaline earth metal salts as TNF-alpha inhibitor in a topical composition and composition obtained therefrom |
US5667790A (en) * | 1995-08-14 | 1997-09-16 | Sellers, Jr.; Billy B. | Aluminum chlorhydrate as a treatment for acne and rosacea |
KR20010013377A (en) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | Mild, leave-on antimicrobial compositions |
US5981499A (en) * | 1998-02-20 | 1999-11-09 | Atlantic Biomed Corporation | Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa |
US20020015726A1 (en) * | 2000-06-30 | 2002-02-07 | Scamilla Aledo Maria Aparecida De Carvalho | Dressings and bandages comprising same |
-
2003
- 2003-12-04 US US10/727,376 patent/US7258875B2/en not_active Expired - Fee Related
-
2004
- 2004-11-30 GB GB0612417A patent/GB2426454A/en not_active Withdrawn
- 2004-11-30 CN CNA2004800281669A patent/CN101262871A/en active Pending
- 2004-11-30 WO PCT/US2004/040038 patent/WO2005055927A2/en active Application Filing
- 2004-11-30 CA CA002539003A patent/CA2539003A1/en not_active Abandoned
- 2004-11-30 JP JP2006542673A patent/JP2007513162A/en active Pending
- 2004-12-03 TW TW093137394A patent/TW200520762A/en unknown
-
2007
- 2007-08-20 US US11/841,341 patent/US20080020059A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4595591A (en) * | 1979-09-27 | 1986-06-17 | Solco Basel Ag | Use of dilute nitric acid solutions for treating certain skin lesions |
US5866168A (en) * | 1995-10-26 | 1999-02-02 | Societe L'oreal S.A. | Dermatological/pharmaceutical compositions comprising lanthanide, manganese, tin, zinc, yttrium, cobalt, barium and/or strontium salts as substance P antagonists |
Non-Patent Citations (1)
Title |
---|
vol. 18TH ED. 1990 article 'Remington's Pharmaceutical Sciences' * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2940121A1 (en) * | 2008-12-23 | 2010-06-25 | Oreal | Composition for the care of greasy skin, especially for eliminating bacteria responsible for acne, contains a combination of phthalamidoperhexanoic acid and zinc salicylate |
EP2233128A1 (en) | 2009-03-25 | 2010-09-29 | Cognis IP Management GmbH | Cosmetic composition |
WO2010108619A1 (en) | 2009-03-25 | 2010-09-30 | Cognis Ip Management Gmbh | Cosmetic composition containing calcium citrate and n-acylated aminoalcohol derivative to prevent dry skin and signs of cutaneous ageing |
US8592484B2 (en) | 2009-03-25 | 2013-11-26 | Cognis Ip Management Gmbh | Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative to prevent dry skin and signs of cutaneous ageing |
US8937100B2 (en) | 2009-03-25 | 2015-01-20 | Cognis Ip Management Gmbh | Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative |
Also Published As
Publication number | Publication date |
---|---|
KR20070000393A (en) | 2007-01-02 |
TW200520762A (en) | 2005-07-01 |
WO2005055927A3 (en) | 2006-11-09 |
US20050123620A1 (en) | 2005-06-09 |
CN101262871A (en) | 2008-09-10 |
GB2426454A (en) | 2006-11-29 |
JP2007513162A (en) | 2007-05-24 |
GB0612417D0 (en) | 2006-08-30 |
US7258875B2 (en) | 2007-08-21 |
US20080020059A1 (en) | 2008-01-24 |
CA2539003A1 (en) | 2005-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7258875B2 (en) | Compositions and methods for topical treatment of skin infection | |
JP6495183B2 (en) | Compositions and methods for treating surface wounds | |
JP5722757B2 (en) | Ionic silver complex | |
DE60210441T2 (en) | MEDICAMENT OR PLASTER CONTAINS A METAL SUCH AS SILVER, GOLD, PLATINUM OR PALLADIUM AS AN ANTIMICROBIAL ACTIVE INGREDIENT AND ITS USE IN THE TREATMENT OF SKIN INFUSION | |
US20050186288A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
CA2900379C (en) | Oral antiseptic composition for the treatment of oral mucositis. | |
RU2211022C2 (en) | Method for treating surface aphthous ulcers at mouth cavity mucosa and local medicinal preparation for treating ulcers at mouth mucosa | |
WO2001049302A1 (en) | Compositions and methods for facilitating skin growth and managing skin conditions | |
EP3164139B1 (en) | Topical compositions and methods for treating wounds | |
CA2742389A1 (en) | Topical treatment of skin infection | |
US8513225B2 (en) | Composition and method for topical treatment of skin lesions | |
EP0664695A1 (en) | Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection | |
US3764669A (en) | Method of making microbiocidal complexes | |
JPS6054932B2 (en) | therapeutic composition | |
KR20060136363A (en) | Compositions and methods for topical treatment of skin infection | |
JPS60152415A (en) | Remedy for pimple and pharmaceutical preparation for remedying pimple consisting of carrier impregnated therewith | |
US20240024351A1 (en) | TOPICAL COMPOSITION FOR DESTROYING, in vivo, AN EXTERNAL HYPERPLASTIC TISSUE, SUCH AS, BUT NOT LIMITED TO, A VIRAL SKIN LESION, SUCH AS, BUT NOT LIMITED TO, A VIRAL WART | |
HU221676B1 (en) | Pharmaceutical composition, containing ethanol or water-ethanol solution having iodine and silver nitrate and process for producing it | |
JPWO2009081581A1 (en) | Composition for treating or preventing atopic dermatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480028166.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2539003 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067006742 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 941/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006542673 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0612417.6 Country of ref document: GB Ref document number: 0612417 Country of ref document: GB |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067006742 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase |